<SEC-DOCUMENT>0001104659-24-060659.txt : 20240513
<SEC-HEADER>0001104659-24-060659.hdr.sgml : 20240513
<ACCEPTANCE-DATETIME>20240513170849
ACCESSION NUMBER:		0001104659-24-060659
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240513
DATE AS OF CHANGE:		20240513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Transcode Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001829635
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811065054
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40363
		FILM NUMBER:		24940224

	BUSINESS ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
		BUSINESS PHONE:		857-301-6857

	MAIL ADDRESS:	
		STREET 1:		6 LIBERTY SQUARE
		STREET 2:		#2382
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02109
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2413608d2_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section 14(a) of
the </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934 </B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Wingdings">x</FONT>
Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Preliminary Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Proxy Statement</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Definitive Additional Materials</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Soliciting Material Pursuant to &sect;240.14a-12</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TransCode Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s) Filing Proxy Statement, if
other than the Registrant) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt">No fee required. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt">Fee paid previously with preliminary materials. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2413608d2_def14aimg001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>TransCode Therapeutics Publishes Open Letter
with regard to Reverse Stock Split Proposal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">BOSTON, MA, May 13, 2024 (GLOBE
NEWSWIRE) - </FONT><B>T<FONT STYLE="background-color: white">ransCode Therapeutics, Inc. (&#8220;TransCode&#8221; or the &#8220;Company&#8221;)
(NASDAQ: RNAZ)</FONT></B><FONT STYLE="background-color: white">, the RNA oncology company committed to more effectively treating cancer
using RNA therapeutics, today announced publication of an open letter to shareholders with regard to Reverse Stock Split proposal. The
text of the letter is below. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">An Open Letter to Shareholders of TransCode Therapeutics,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Open Letter to Shareholders</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Shareholder,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As you may have seen, we have filed an amended proxy statement in connection
with our Annual Meeting scheduled for June 13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One of the proposals in the proxy provides for authorizing the Board
of Directors, if they believe it is the best interests of the company and shareholders, to effect a reverse split of our stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This has been one of the most difficult deliberations we have had.
This is NOT something any of the directors (or management) wishes to do &#8211; and hopes that it won&#8217;t be needed. The reason for
the re-quested authorization is that our common stock did not close at $1.00 per share or more for any ten day period ended May 6, the
so-called Minimum Bid Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As we noted in the 8-K filed May 10, Nasdaq has notified us that because
we did not meet the Mini-mum Bid Requirement by May 6, the Nasdaq staff is recommending that our shares be delisted. We have the right,
and we intend to, file a request for a Nasdaq Panel Hearing at which hearing we intend to appeal the decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our stock has closed above $1.00 per share for four consecutive days
through May 10. Even if it con-tinues to close above $1.00 per share for another six trading days (longer hopefully), it will not guaran-tee
that the Panel will provide any leeway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The reason for requesting the authority to do the reverse split is
that, as a last resort, we can inform the Panel that shareholders have authorized a reverse split. There is also no assurance that the
au-thorization (alone or in combination with other reasons we will provide the Panel) will result in our stock not being delisted, but
the company and its advisors believe this is our best chance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe having our stock continue to be listed on The Nasdaq Capital
Market will be valuable in a number of ways in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hope to not have to effect a reverse split, but we also believe
that our shareholders are best served by doing everything we can to continue to be Nasdaq-listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We share your frustration and greatly appreciate your support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your Board and Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This release contains &#8220;forward-looking statements&#8221; within
the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements in this press release are based on
management&#8217;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties
include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical
trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode&#8217;s
planned regulatory submissions; risks associated with TransCode&#8217;s planned clinical trials for its product candidates; risks associated
with obtaining, maintaining and protecting intellectual property; risks associated with TransCode&#8217;s ability to enforce its patents
against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies
developing products for similar uses; risks associated with TransCode&#8217;s financial condition and its need to obtain additional funding
to support its business activities, including TransCode&#8217;s ability to continue as a going concern; risks associated with TransCode&#8217;s
dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties,
and other important factors, any of which could cause TransCode&#8217;s actual results to differ from those contained in or implied by
the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in TransCode&#8217;s Annual Report on Form 10-K for
the year ended December 31, 2023, as well as discussions of potential risks, uncertainties and other important factors in any subsequent
TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release;
TransCode undertakes no duty to update this information unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For more information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TransCode Therapeutics, Inc.<BR>
Tom Fitzgerald, Interim CEO and CFO<BR>
tom.fitzgerald@transcodetherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2413608d2_def14aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2413608d2_def14aimg001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% 50# 2(  A$! Q$!_\0
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MP-X/^*6C^#Y-1222+[/I_BRR^$_BG1-1M)#'))#=65[$TT:QRA!%("WE-O\
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MEKVNK6W1[:2 2$X'?' S]/ICL*;Y@!P7 .<8W<YP#C&>N"#CK@@]*_)32?\
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M>4E).+O9/8R^KQJ8_P!M*FX>SPLH0KNUG.3;M%W;NEO>*WW/E3_@G1_P5_\
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M4XAN;C]BWXSVMI:SWMW)IFC&&TLT$]U<$^(-+5EM[<,LLSHN975%)\M6*AF
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M*0?,Q)N4MY:*<+XU_">Q^,GPQ\3?#._U>\T*P\1KH1N]2M(89IK?^Q-=TOQ
MK11S#R5$LFE10OM";0?E( Q47IZ:2WUT7?5;ZZ;;&G+5MO&_J^WIWW,_XX_%
MV[^$7AW1+W3]#7Q-XE\:^//"GPU\#Z$UU_9UI?>*/%UW<16DFJ:FWFFUTW3;
M*TOM5U)HK:246EBZ0!Y;A1'K> I?C-;3ZBGQ/G^&NH6)MXYM)U3P1!XCTFY6
MY>9DFLM0TC79]4C,%NFT)JMOJN+D8E%E$)!&MOXG_"[PW\6?#;>']?%_:26^
MH:3XC\.^(=+N)['6?"_BW0+@WGAWQ1I%W:R6TT&JZ5<D2Q9;R98);FPN(WM+
MJYADX?X5?#GXP>"Y]:U'XK?'_6?C-<W,:6>C63^ O!OPYT/1-*CE<_;+BQ\*
MV-U/KOBB= LNJZW--IFD7EV99-)\-:!8R0Z;:BC&?*HM1:=Y<UUS)V7+&UUW
M;YN5>?04I5*=VTY<UU%0U:W=VG;2S2TN[^1P_C?X[>/] ^.(^':6/@;PEX0@
ML?!=UHWB'X@-XDM(/BA>^);[6;/7]#\'Z_IT#:'HFK^#Y-.L+>>VUN.[DU>Z
MUVP\A+>)LGU7Q3J'QATGQ)&?"EGHOB70KR]M8OLNJPG21IUFWAWQ?=7$HU.*
M\?[1)#K=CX9A_P"/*+_1;F\A*O-<0W%KYO\ $GX#^*/B!XNBU"V^+_B;PS\/
M=;GT1OB'\*[K0-&\7:/XB_X1][:?3+KP5J.J-'??"O6S>0K+KNJ>'&UNPUIH
MUNYK2UU9!J%?6'V>+D[?F8 %\MO(!) +D[B!N8<D\$CO6E;V4534+-\K4[*Z
M^RUKWWNDVMG?6R*#DW-R32;C;FT>SOI?O_3W,CP]=:Q=Z/I,^NP6MMK$UC:R
M:M;67F&UM[UX7:XCMGE=W:%90JIN+L%Y+-NR-VF[%R&ZE=VW)SMW=<>G' ]!
MD#BG5S'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 (RA@58 JP((/<$$$?B"13!%& 0$4!O,R,<'S6+R9_P!]F9CZ
MDGUHHH <40\[1GCU[;<?^@K^0IHAB5=@C4)@#;CC "J!CT 1!CIA1110 >5'
M\V$4;@ V  2 2P!(P< DD>F33?L\.2WEIN(0$XY(1VD3)_V79F!ZY))HHKDE
M4FI22D[*32V[^@$A52 ". 00/0@Y'Y'G'2D$48.0H!SG/?/6BBNM;+T7Y -2
M&*,H4C53'&(4('W8AMP@_P!D;5X]A3]JD %00"" 0#@@Y!&>X/(]#112:NK/
MJ GEIP-HX)(XY!.02#U!()!QC@D=#3@H&,#IG'X]?Y444E"*=TG?U878QHHV
MZH#RC8[;HW62,XZ95U5A[@4HC0'(49VE>Y^4XR,'@@X'6BBJ =@>G?/XYSG\
MS2,BN"'564@@JP!!!X((/!!'8@BBBDXJ5K]/-K\@$\N/^XIX Y4'@'('(Z @
M$#H#S3Z**%%+;KYM_F 4444P"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
